Actavis could make out big time with FDA’s knock to Mallinckrodt, Kudco drugs

Eric Palmer While the industry is fixated on whether Actavis will save Allergan from a hostile takeover by Valeant or whether Pfizer might be sizing up a run at Actavis, there was a ...

Can Amgen sue its way to the top of the PCSK9 pile?

Damian Garde In the race to commercialize a new class of potential cardiovascular blockbusters, Amgen and its team of lawyers have filed a patent suit to fend off the advance of rivals ...

EU’s top regulator canned on a technicality

Damian Garde The European Medicines Agency didn't follow procedure when it appointed Executive Director Guido Rasi, a court has ruled, forcing the continent's top drug regulator ...

Roche’s Avastin wins FDA green light in ovarian cancer

Carly Helfand Roche's Avastin is now two-for-two on converting recent FDA priority review designations into label expansions. Just three months after the cancer giant nabbed the ...

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Carly Helfand Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan–and word is it could happen quickly. FiercePharma News

AstraZeneca trumpets a preclinical long shot in bid to burnish Brilinta’s prospects

John Carroll It's not often that a Big Pharma company puts out a press release announcing the launch of a preclinical drug program. The mortality rate of therapies that have yet ...

Blueprint Medicines banks $50M for its personalized take on cancer

Damian Garde Third Rock Ventures startup Blueprint Medicines has hauled in a $ 50 million C round, cash that'll see its way through clinical trials and keep its promising platform ...

Some psych experts want FDA to yank black-box warning on antidepressants

Emily Wasserman In the 10 years since the FDA found that antidepressants carried an increased risk of suicidal thoughts and behaviors in teens and slapped a black box warning on the ...

Threshold shares surge as PhIII cancer program enters FDA’s fast track

John Carroll Shares of Threshold Pharmaceuticals jumped about 10% this morning on news that the FDA is granting fast-track status to TH-302, the company’s sole therapy now in ...

Take as directed? U.K. health service teams with academics, pharmacy on drug adherence

Tracy Staton It's an established fact: Many patients don't take their meds as directed. Another established fact: That failure costs the healthcare system hundreds of billions. ...

U.S. judge blesses Pfizer’s $325M settlement in Neurontin class action

Carly Helfand A decade-long class action lawsuit against Pfizer over alleged off-label Neurontin marketing is finally wrapping up, with U.S. District Judge Patti Saris approving a $ ...

Amgen and AstraZeneca’s psoriasis drug beats blockbuster Stelara in head-to-head trial

John Carroll Amgen and its Big Pharma partner AstraZeneca have roped in another round of promising Phase III plaque psoriasis data for their IL-17 blockbuster contender brodalumab, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS